FDA approval lets Foamix set its maiden acne therapy on course for US market launch

FDA approval lets Foamix set its maiden acne therapy on course for US market launch

Source: 
Endpoints
snippet: 

Months ago, Foamix leaned on its biggest shareholders — Perceptive Advisors and OrbiMed — to financially grease its wheels, ahead of the FDA decision date for its acne therapy. On Friday, that approval came in — and the topical formulation of the antibiotic minocycline is set for a January launch.